Press Releases

- First therapeutic approved for the treatment of aTTP, a rare blood-clotting disorder

Nearly 70 million doses to be manufactured this season

- Company invests €66 million in Chengdu, Sichuan province, China

- Toujeo (insulin glargine injection 300 Units/mL) met primary endpoint in lowering blood sugar levels and was non-inferior to insulin degludec in adults with type 2 diabetes not previously on insulin